Read full story

U.S. economy ‘in a better position’ than most countries despite recession risk, Biden adviser says

Biden says reducing tariffs on China is under consideration, weighs asking OPEC to pump more oil

U.S. and 12 countries join new Indo-Pacific trade pact, Biden says US recession not evitable

Pfizer, BioNTech COVID-19 vaccine for children aged 6 months to 5 years meets EUA criteria

Shares of Pfizer Inc. undefined rose 0.3% and BioNTech SE undefined rallied 1.3% in premarket trading, after the drug makers said three doses of it COVID-19 vaccine for children aged six months to five years "met all immunobridging criteria" required for Emergency Use Authorization by the U.S. Food and Drug Administration. The companies said the vaccine showed 80.3% efficacy in an analysis of three doses at a time when omicron was the dominant variant, with a favorable safety profile, similar to placebo. "The study suggests that a low 3-ug dose of our vaccine, carefully selected based on tolerability data, provides young children with a high level of protection against the recent COVID-19 strains," said BioNTech Chief Executive Ugur Sahin. "We are preparing the relevant documents and expect completing the submission process to the FDA this week, with submissions to EMA and other regulatory agencies to follow within the coming weeks." Pfizer's stock has declined 11.1% and BioNTech shares have dropped 36.8% year to date through Friday, while the S&P 500 undefined has lost 18.1%.

Ginni Thomas urged Arizona lawmakers to pick a ‘clean slate’ of electors just days after Trump’s loss to Biden

Read full story

Elon Musk called ESG a scam — did the Tesla chief do investors a favor?

Read full story

Nvidia’s data-center sales likely to eclipse gaming — that might not be a good thing

Read full story

Biotech is in ‘a Category 5 storm, the same as energy in 2020’ — why contrarians say the sector is a buy

Read full story

Monkeypox is something ‘everybody should be concerned about’ and ‘would be consequential,’ if it spreads, says Biden

Read full story

‘Workers don’t want toys or free food, they want a higher quality of life’: The Great Resistance is here — as companies struggle to get workers back to the office

Read full story

‘At our age should we do this?’ We’re retired, have $5 million in savings and earn $7,000 a month. Should we spend over $2.1 million to build our dream home?


Partner Center


Customize MarketWatch

Have Watchlists? Log in to see them here or sign up to get started.

  • Symbol Last Change Chg Change % Chg % Volume
No Items in Watchlist

There are currently no items in this Watchlist.

No Saved Watchlists

Create a list of the investments you want to track.

Uh oh

Something went wrong while loading Watchlist.

Recently Viewed Tickers

No Recent Tickers

Visit a quote page and your recently viewed tickers will be displayed here.

Read full story

Amazon no longer a ‘focus’ at Citigroup, as stock falls toward longest weekly losing streak in 14 years

HPE, Pure Storage stocks drop after Cisco creates fear about business-spending slowdown

ImmunoGen's stock is up 12% after the FDA accepts application for new ovarian-cancer therapy

Shares of ImmunoGen Inc. jumped 12.0% in premarket trading on Monday after the company said the Food and Drug Administration accepted an application for its experimental ovarian-cancer treatment. The mirvetuximab soravtansine monotherapy has a Prescription Drug User Fee Act action date of Nov. 28. ImmuoGen said it is still enrolling patients in a confirmatory trial, with plans to announce data from that study early next year. The company's stock has declined 51.7% this year, while the broader S&P 500 is down 18.1%.

Broadcom reportedly in talks to buy VMware